Modulating 5-HT 4 and 5-HT 6 receptors in Alzheimer’s disease treatment
| Autor: | Patrick Dallemagne, Delphine Karila, Julien Lalut, Christophe Rochais |
|---|---|
| Přispěvatelé: | Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Institut de Chimie des Substances Naturelles (ICSN), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC) |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Amyloid pathology Disease [CHIM.THER]Chemical Sciences/Medicinal Chemistry Biology Pharmacology 5-HT4 receptors 03 medical and health sciences 0302 clinical medicine neurodegenerative disease Drug Discovery medicine Dementia Receptor multitarget-directed ligand medicine.disease 3. Good health Clinical trial 030104 developmental biology Alzheimer's disease treatment Molecular Medicine 5-HT6 receptors Neuroscience Alzheimer’s disease 030217 neurology & neurosurgery |
| Zdroj: | Future Medicinal Chemistry Future Medicinal Chemistry, Future Science, 2017, 9 (8), pp.781-795. ⟨10.4155/fmc-2017-0031⟩ |
| ISSN: | 1756-8919 |
| DOI: | 10.4155/fmc-2017-0031⟩ |
| Popis: | Alzheimer’s disease (AD) is the most common form of dementia affecting millions of patients worldwide which can only be treated with symptomatic drugs. Among the numbers of biological targets which are today explored in order to prevent or limit the progression of AD, the modulation of 5-HT6R and 5-HT4R appeared to be promising. This modulation has been proved to enhance the cognition in AD through modulation of the neurotransmitter system but could also be beneficial in order to limit the amyloid pathology. This review will describe recent advances in the understanding of this modulation as well as the medicinal chemistry of 5-HT6R or 5-HT4R ligands from synthesis to ongoing clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|